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Background: Macular edema is a known complication even after uneventful cataract surgery. 
The chronic use of prostaglandin analogs is a risk factor for the development of pseudophakic 
cystoid macular edema (CME). Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered 
first-line therapy but refractory postsurgical CME represents a therapeutic challenge, as there 
is not an evidence-based treatment.
Objective: To report the use of a single implant of intravitreal dexamethasone for tafluprost-
associated pseudophakic CME refractory to NSAIDs and to sub-Tenon’s corticosteroid 
injections.
Case report: A 64-year-old female with ocular hypertension treated with tafluprost experi-
enced decreased vision (visual acuity 20/60) and metamorphopsia 2 months after uneventful 
cataract extraction. Spectral domain optical coherence tomography (SD-OCT) revealed CME. 
After 1 month of topical and oral NSAIDs, CME was still evident on SD-OCT (visual acuity 
20/50). Two sub-Tenon’s betamethasone injections were performed at a 2-week interval. As 
CME was still present, 2 months after the diagnosis of CME (visual acuity 20/40), the patient 
underwent a single dexamethasone intravitreal implant. One month later, macular appearance 
was normal, and visual acuity increased to 20/30. This result was maintained throughout the 
6 months of follow-up.
Conclusion: In this report, a single implant of intravitreal dexamethasone successfully 
treated pseudophakic CME associated with the use of prostaglandin analogs unresponsive to 
NSAIDs and sub-Tenon’s betamethasone. The results of this report need to be corroborated 
by powered, prospective, randomized trials. The need for repeated treatments as well as the 
retreatment interval in patients requiring more than a single injection are issues still needing 
further investigations.
Keywords: prostaglandin-induced refractory cystoid macular edema, intravitreal dexamethasone 
implant, tafluprost, cataract surgery, pseudophakic cystoid macular edema
Introduction
Macular edema is a well-recognized complication of cataract surgery. Diabetic retin-
opathy, uveitis, chronic use of prostaglandin analogs (PGAs), and surgical complica-
tions are well-known risk factors for postsurgical cystoid macular edema (CME).1
Inflammation is considered the main etiologic factor in the pathogenesis of 
CME, and current evidence indicates that it depends on the breakdown of the blood–
retinal membrane induced by the upregulation of inflammatory mediators, leading to 
increased vascular permeability and accumulation of fluid in the  perifoveal retina.2 
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Topical nonsteroidal anti-inflammatory drugs (NSAIDs) 
and corticosteroids are considered first-line therapy for 
postsurgical CME;1 however, in some patients CME 
does not resolve after medical therapy. These patients 
represent a challenge for the clinicians, as for refractory 
CME there is no standardized treatment, and although 
many approaches have been described, available therapies 
have showed conflicting results.1,2 Matsuura et al recently 
reported a case of tafluprost-associated pseudophakic CME 
successfully treated with a single sub-Tenon’s triamcino-
lone injection.3 We present a case of tafluprost-associated 
pseudophakic CME refractory to NSAIDs and steroid 
sub-Tenon’s injections successfully treated with a single 
intravitreal dexamethasone implant. This is the first report 
on the use of a dexamethasone implant for the treatment of 
prostaglandin-induced pseudophakic CME.
Case
A 64-year-old female Caucasian patient was referred to 
our hospital for decreased monocular vision and metamor-
phopsia. Her general history was unremarkable. Her ocular 
history revealed uneventful cataract surgery in her left eye 
approximately 2 months before the onset of symptoms. 
She had been taking tafluprost once a day for 1 year for 
ocular hypertension. Visual acuity (VA) was 20/60, +0.75. 
The anterior chamber was crystal clear, as was the poste-
rior chamber intraocular lens. Intraocular pressure (IOP) 
was 16 mmHg. Fundoscopy and spectral domain optical 
coherence tomography (SD-OCT) revealed a CME with 
serous retinal detachment (SRD) (Figure 1A). Diagnosis 
was confirmed by fluorescein angiography. The fellow eye 
was healthy. The patient was treated with 0.3% nepafenac 
ophthalmic suspension (Nevanac®; Alcon Laboratories, 
Figure 1 (A) two months after cataract surgery, CMe with srD is shown on sD-OCt. NsaIDs therapy is started. (B) Month 1: after 1 month of oral and topical NsaIDs, 
srD disappeared, but CMe was still evident on sD-OCt. sub-tenon’s steroid injections are scheduled. (C) Month 2: after two consecutive injections of sub-tenon’s 
betamethasone CMe is reduced, but still evident on sD-OCt. Intravitreal dexamethasone implant is scheduled. (D) Month 3: after one intravitreal implant of 0.7 mg 
dexamethasone, sD-OCt showed resolution of CMe.
Abbreviations: CMe, cystoid macular edema; srD, serous retinal detachment; sD-OCt, spectral domain optical coherence tomography; NsaIDs, nonsteroidal anti-
inflammatory drugs.
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Fort Worth, TX, USA) four times a day for 1 month and 
indomethacin 50 mg (Indoxen®; Sigma-Tau, Rome, Italy) 
bid for 2 weeks. Tafluprost was discontinued and switched 
to timolol 0.50% twice a day. After 1 month of medical 
therapy, VA improved to 20/50 and SD-OCT showed resolu-
tion of the SRD; however, CME was still present (Figure 1B). 
Two sub-Tenon’s injections of 4 mg betamethasone were 
performed at 2-week intervals. One month after the first 
sub-Tenon’s injection (2 months after the diagnosis of CME), 
VA was 20/40 and SD-OCT still showed CME (Figure 1C). 
At this time, we opted for an intravitreal 0.7 mg dexametha-
sone implant (Ozurdex®; Allergan, Irvine, CA, USA). The 
procedure was uneventful, and 1 month later VA improved 
to 20/30, with SD-OCT showing resolution of the CME 
(Figure 1D). These results were confirmed over 6 months 
of follow-up. IOP was between 16 and 24 mmHg during the 
first month after the dexamethasone injection, and between 
14 and 19 mmHg throughout the follow-up.
Discussion
We report a case of refractory prostaglandin-induced 
pseudophakic CME. After 1 month of topical and systemic 
NSAIDs and two consecutive injections of sub-Tenon’s 
steroid, CME was still evident on SD-OCT. Two months 
after the diagnosis of CME, a single intravitreal implant 
of dexamethasone effectively resolved the CME, improv-
ing visual acuity to 20/30. These results were stable over 
6 months of follow-up.
PGAs are known risk factors for postsurgical CME.4 
Tafluprost, the most recent PGA commercially available, has 
shown similar efficacy compared to other PGAs and a safe 
profile.5 To the best of our knowledge, this is the first report 
of the use of a dexamethasone implant for prostaglandin-
induced pseudophakic CME and the second case of pseu-
dophakic CME associated with tafluprost.3 Several treatments 
have been described for pseudophakic CME, and although no 
standardized treatment exists, topical NSAIDs have become 
the mainstay of pseudophakic CME therapy and prophylaxis. 
Among the proposed approaches, the use of anti-VEGF has 
been suggested for the treatment of postsurgical CME, as 
VEGF is considered to play an important role in inflammation 
and in vascular permeability.1 However, studies exploring 
the efficacy of anti-VEGF for refractory pseudophakic CME 
have reported mixed findings.6–9
Corticosteroids are widely used in CME, due to their 
capability to control the inflammatory process involved in 
the development of macular edema. Corticosteroids can be 
delivered by topical, periocular, and subconjunctival routes. 
Among them, the sub-Tenon’s approach has been proven to 
achieve the highest vitreous levels, and has been shown to 
be effective for postsurgical CME in some3,10 but not all11 
reports. Intravitreal injection of corticosteroids is also possi-
ble; however, evidence supporting this approach in pseudopha-
kic CME is limited. In addition, the effect of the intravitreal 
injection of the drug is transient, needing multiple procedures 
with increased risk of endophathalmitis.1 Although there 
are studies showing that a single sub-Tenon’s injection of 
triamcinolone successfully treated pseudophakic CME asso-
ciated with tafluprost, travoprost, and latanoprost,3,12 in the 
current case and in a report by Brynskov et al11 sub-Tenon’s 
injections of corticosteroids were not effective in resolving 
prostaglandin-induced CME. Because our case was unre-
sponsive to topical NSAIDs and sub-Tenon’s steroids, we 
opted for a dexamethasone implant. The sustained-release 
intravitreal dexamethasone implant has been proposed and 
has been proven to be effective for the treatment of CME aris-
ing from retinal vein occlusion and for the treatment of non-
infectious uveitis affecting the posterior pole.13,14 Recently 
the efficacy of dexamethasone intravitreal implants has been 
reported even in recalcitrant cases of retinal vein-occlusion 
CME unresponsive to multiple intravitreal bevacizumab 
injections.15 The efficacy of the dexamethasone implant for 
refractory CME in retinal vein occlusion has encouraged 
its use even for postsurgical CME. Nowadays, the use of 
dexamethasone implants in refractory postsurgical CME is 
an emerging indication16 recently described in vitrectomized 
eyes17 and after cataract extraction11,18–21 (Table 1). Some 
authors have suggested that an intravitreal implant of dexam-
ethasone can be considered as first-line therapy for refractory 
postsurgical CME, among other intravitreally administered 
drugs.16,17 When corticosteroids are adopted, the route of 
administration is crucial for the efficacy of the therapy.
The use of intravitreal dexamethasone shows some 
advantages compared to the sub-Tenon’s administration 
of steroids, which may explain the success of the former 
approach in the current case and in the study by Brynskov 
et al.11 First, the intravitreal route can achieve higher vitreous 
drug levels compared to the sub-Tenon’s route.22 Second, 
whereas the subconjunctival route is associated with a 
short drug half-life, a sustained-release intravitreal dex-
amethasone implant allows a stabler and longer-lasting 
intravitreal delivery of the drug.16 In addition, the success 
of the dexamethasone implant compared to the use of other 
intravitreal steroids17,21 may be explained by the fact that 
dexamethasone is one of the most potent corticosteroids, 
showing, eg, anti-inflammatory activity sixfold higher than 
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Table 1 published studies on the use of dexamethasone implant for postsurgical cystoid macular edema
Study CME etiology Enrolled  
patients
Medical  
therapy
Periocular/ 
IVT therapy
Dexamethasone-
implant injections
Follow-up
Williams et al18 pseudophakic CMe 8 –b – 1 6 months
Meyer and schönfeld19 pseudophakic CMe 1 – 3 IVt dexamethasone  
(0.4 mg)
1 3 months
Merkoudis and Granstam17 postsurgical CMea 1 topical NsaIDs
topical steroids
Oral CaI
2 IVt triamcinolone
1 IVt ranibizumab
1 10 months
Brynskov et al11 pseudophakic CMe 1 – 1 st triamcinolone
5 IVt ranibizumab
2 6 months
Furino et al20 pseudophakic CMe 11 topical NsaIDs
topical steroids
– 1 6 months
Dutra Medeiros et al21 pseudophakic CMe 9 topical NsaIDs
topical steroids
Oral CaI
IVt anti-VeGFc
IVt triamcinolonec
1 6 months
Current report prostaglandin-induced CMe 1 topical NsaIDs
Oral NsaIDs
2 st betamethasone 1 6 months 
Notes: aCataract and macular hole surgery; bmedical therapy not specified; use of systemic, periocular, or intraocular corticosteroids was prohibited within 30 days 
of enrollment; cnumber of procedures not reported.
Abbreviations: CME, cystoid macular edema; IVT, intravitreal; ST, sub-Tenon’s; CAI, carbonic anhydrase inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs.
triamcinolone.16 Increases in IOP should be ruled out by 
close follow-up in any patients treated with dexamethasone 
implants, especially when dealing with patients affected by 
ocular hypertension or glaucoma; however, in our patient, 
IOP was well controlled, except in the first month after the 
intravitreal dexamethasone implant, when a mild, transient 
increase in IOP was reported.
Conclusion
We present the first case of prostaglandin-induced pseu-
dophakic CME recalcitrant to NSAIDs and sub-Tenon’s 
triamcinolone successfully treated by a single implant of 
intravitreal dexamethasone. Side effects were not reported, 
and the result was maintained throughout the 6-month 
follow-up.
Our case confirms the results of previous reports, and 
supports the emerging indication of dexamethasone implants 
for the treatment of refractory postsurgical CME. In addition, 
our results show that even in patients with ocular hyperten-
sion, an intravitreal dexamethasone implant can be used with 
a limited effect on IOP, although in such patients, close IOP 
control is mandatory.
Further powered, randomized, prospective studies with 
longer follow-up are warranted to corroborate this result 
and to elucidate the need for repeated treatments, as well 
as the retreatment interval in patients requiring more than a 
single injection.
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